journal
MENU ▼
Read by QxMD icon Read
search

Journal of the Advanced Practitioner in Oncology

journal
https://www.readbyqxmd.com/read/30333941/the-smartie-program-a-novel-initiative-to-evaluate-the-impact-of-ap-continuing-education-on-clinical-practice
#1
EDITORIAL
Sandra E Kurtin, Constance Visovsky, Erik D Brady, Alana L K Brody
No abstract text is available yet for this article.
November 2017: Journal of the Advanced Practitioner in Oncology
https://www.readbyqxmd.com/read/30333940/oral-cancer-therapy-the-importance-of-adherence
#2
EDITORIAL
(no author information available yet)
No abstract text is available yet for this article.
November 2017: Journal of the Advanced Practitioner in Oncology
https://www.readbyqxmd.com/read/30333939/hepatitis-c-virus-in-the-hematology-oncology-patient
#3
REVIEW
Wendy H Vogel
No abstract text is available yet for this article.
November 2017: Journal of the Advanced Practitioner in Oncology
https://www.readbyqxmd.com/read/30333938/lenvatinib-in-the-treatment-of-differentiated-thyroid-cancer-and-advanced-renal-cell-carcinoma
#4
REVIEW
Urvi J Patel, Megan May
No abstract text is available yet for this article.
November 2017: Journal of the Advanced Practitioner in Oncology
https://www.readbyqxmd.com/read/30333937/immunotherapy-through-the-years
#5
REVIEW
Jessica Eno
No abstract text is available yet for this article.
November 2017: Journal of the Advanced Practitioner in Oncology
https://www.readbyqxmd.com/read/30333936/li-fraumeni-syndrome
#6
REVIEW
Wendy H Vogel
No abstract text is available yet for this article.
November 2017: Journal of the Advanced Practitioner in Oncology
https://www.readbyqxmd.com/read/30333935/symptom-management-strategies-for-patients-receiving-anaplastic-lymphoma-kinase-inhibitors-for-non-small-cell-lung-cancer
#7
REVIEW
Jennifer Jacky, Christina Baik
No abstract text is available yet for this article.
November 2017: Journal of the Advanced Practitioner in Oncology
https://www.readbyqxmd.com/read/30333934/practical-strategies-for-management-of-lenalidomide-associated-cytopenias-in-myelodysplastic-syndromes-with-del-5q
#8
REVIEW
Sandra E Kurtin, Jean A Ridgeway, Sara Tinsley
CASE STUDY A male patient aged 67 years with a 2-year history of refractory anemia and myelodysplastic syndromes (MDS) with del(5q) started lenalidomide (Revlimid) treatment as a participant in the MDS-001 trial (List et al., 2005). At the time of the study, this patient had been transfusion-dependent since 2001, and at study entry he had received a total of 12 units of red blood cells (RBCs). The patient started lenalidomide at 25 mg daily for 21 days of each 28-day cycle on April 2, 2002. (Please note that as a result of subsequent trials, the approved starting dose for lenalidomide in patients with del[5q] MDS is 10 mg...
November 2017: Journal of the Advanced Practitioner in Oncology
https://www.readbyqxmd.com/read/30333933/managing-tumor-lysis-syndrome-in-the-era-of-novel-cancer-therapies
#9
REVIEW
Ali McBride, Steven Trifilio, Nadine Baxter, Tara K Gregory, Scott C Howard
Abstract Tumor lysis syndrome (TLS) is a potentially life-threatening emergency that can develop rapidly after the release of intracellular contents from lysed malignant cells. The advent of novel and targeted therapies that have improved tumor-killing efficacy has the potential to increase the risk of TLS when used as part of front-line therapy. A recent review of TLS risk in patients with hematologic malignancies treated with newer targeted agents highlighted the need to revisit TLS risk stratification and to describe the practical challenges of TLS prevention, treatment, and monitoring...
November 2017: Journal of the Advanced Practitioner in Oncology
https://www.readbyqxmd.com/read/30333932/integrating-biosimilars-into-oncology-practice-implications-for-the-advanced-practitioner
#10
REVIEW
Christopher J Campen
Biosimilar agents are biologic products that have been shown to be "highly similar" to an already approved reference biologic product. Their integration into clinical practice has the potential to significantly decrease costs for patients, health-care systems, and insurance companies. Through legislation, the US Food and Drug Administration (FDA) approved the Biologics Price Competition and Innovation (BCPI) Act in 2009. In 2010, it was signed into law, allowing for an abbreviated pathway for biosimilar approval...
November 2017: Journal of the Advanced Practitioner in Oncology
https://www.readbyqxmd.com/read/30333931/psychosocial-distress-as-a-factor-in-patients-with-cancer-seeking-support-a-hermeneutic-study
#11
REVIEW
Marjan Mardani-Hamooleh, Haydeh Heidari
No abstract text is available yet for this article.
November 2017: Journal of the Advanced Practitioner in Oncology
https://www.readbyqxmd.com/read/30333930/innovations-in-cancer-therapies-and-rising-costs
#12
EDITORIAL
Pamela Hallquist Viale
No abstract text is available yet for this article.
November 2017: Journal of the Advanced Practitioner in Oncology
https://www.readbyqxmd.com/read/30310727/the-oncology-care-model-for-advanced-practitioners
#13
REVIEW
Wendy H Vogel
No abstract text is available yet for this article.
September 2017: Journal of the Advanced Practitioner in Oncology
https://www.readbyqxmd.com/read/30310726/venetoclax-a-novel-treatment-for-patients-with-del-17p-chronic-lymphocytic-leukemia
#14
REVIEW
Michelle A Borg, Amber Clemmons
No abstract text is available yet for this article.
September 2017: Journal of the Advanced Practitioner in Oncology
https://www.readbyqxmd.com/read/30310725/advice-about-screening-for-prostate-cancer-with-prostate-specific-antigen
#15
REVIEW
Gannel Jean-Pierre
No abstract text is available yet for this article.
September 2017: Journal of the Advanced Practitioner in Oncology
https://www.readbyqxmd.com/read/30310724/role-of-the-advanced-practice-provider-in-clinical-trials-contributions-to-the-management-of-patients-receiving-inotuzumab-ozogamicin
#16
REVIEW
Mary Alma Welch, Joanne C Ryan, Ilene Ann Galinsky
No abstract text is available yet for this article.
September 2017: Journal of the Advanced Practitioner in Oncology
https://www.readbyqxmd.com/read/30310723/brentuximab-vedotin-infusion-reaction-management-a-case-study
#17
REVIEW
Holly Comer, Kimbra Cardwell
We report a case of a grade 3 (Common Terminology Criteria for Adverse Events [CTCAE]) infusion reaction to brentuximab vedotin (Adcetris), in a patient with refractory Hodgkin lymphoma, at a large National Cancer Institute-designated cancer center in the Midwest (National Cancer Institute, 2010). Acute infusion reaction management and subsequent premedication strategies are outlined. Ms. R is a 30-year-old woman who presented with stage IV Hodgkin lymphoma at the age of 29. Initial staging revealed lymphadenopathy above and below the diaphragm, as well as fluorodeoxyglucose (FDG)-avid lung lesions, splenic lesions, and multiple sites of bony involvement...
September 2017: Journal of the Advanced Practitioner in Oncology
https://www.readbyqxmd.com/read/30310722/managing-drug-interactions-in-cancer-therapy-a-guide-for-the-advanced-practitioner
#18
REVIEW
Christopher J Campen, Wendy H Vogel, Pooja J Shah
Mrs. P is a 30-year-old woman who presented to our bone marrow transplant program with myelodysplastic syndrome (MDS). She received a haploidentical allogeneic stem cell transplant with a conditioning regimen consisting of busulfan and cyclophosphamide. This treatment was followed by post-transplant immunosuppression for graft-versus-host disease (GVHD) with cyclophosphamide, mycophenolate mofetil (MMF), and tacrolimus (see Table 1 for medication list). Tacrolimus levels were monitored twice a week with adjustment to a goal range of between 5 and 10 ng/mL...
September 2017: Journal of the Advanced Practitioner in Oncology
https://www.readbyqxmd.com/read/30310721/cancer-pain-management-opioid-analgesics-part-2
#19
REVIEW
Rita J Wickham
Opioid analgesics are the cornerstone of moderate to severe cancer pain management, and do not have ceiling doses unless unmanageable adverse effects occur. Oral, short-acting pure Ī¼ agonists such as morphine are most frequently used, but other agents and administration formulations allow finding the right opioid and dose for most patients. In addition, clinicians must understand the metabolism, pharmacokinetics, and elimination of particular drugs to individualize opioid selection, select initial doses, and appropriately escalate doses to satisfactory pain relief or uncontrollable toxicity...
September 2017: Journal of the Advanced Practitioner in Oncology
https://www.readbyqxmd.com/read/30310720/assessing-the-plain-language-planner-for-communication-about-common-palliative-care-medications
#20
REVIEW
Elaine Wittenberg, Betty Ferrell, Joy Goldsmith
Using plain language to communicate about oncology and palliative care medications and symptoms is recommended as a communication strategy to address patient/family health literacy demands. This study tested the Plain Language PlannerĀ©, a provider tool for communicating about medication and symptoms using plain language. Prior to and immediately following an oncology and palliative care nurse educational session, participants (n = 87) role-played about a symptom and medication. Common symptoms (nausea, constipation, and anxiety) and medications were selected...
September 2017: Journal of the Advanced Practitioner in Oncology
journal
journal
48476
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"